Curo Prime Pharmax Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 06-12-2024
- Paid Up Capital ₹ 2.90 M
as on 06-12-2024
- Company Age 16 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.20 M
as on 06-12-2024
- Satisfied Charges ₹ 2.60 M
as on 06-12-2024
- Revenue 2.93%
(FY 2020)
- Profit 372.30%
(FY 2020)
- Ebitda 1343.68%
(FY 2020)
- Net Worth 8.00%
(FY 2020)
- Total Assets 51.42%
(FY 2020)
About Curo Prime Pharmax
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.90 M.
The company currently has active open charges totaling ₹1.20 M. The company has closed loans amounting to ₹2.60 M, as per Ministry of Corporate Affairs (MCA) records.
Ajay Gupta, Sanjay Chamria, and Kushagar Chamaria serve as directors at the Company.
- CIN/LLPIN
U24232RJ2008PTC025682
- Company No.
025682
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jan 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Curo Prime Pharmax?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay Gupta  | Director | 06-May-2022 | Current |
| Sanjay Chamria | Director | 03-Apr-2010 | Current |
| Kushagar Chamaria | Director | 28-May-2022 | Current |
Financial Performance and Corporate Structure Insights of Curo Prime Pharmax.
Curo Prime Pharmax Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 2.93% increase. The company also saw a substantial improvement in profitability, with a 372.3% increase in profit. The company's net worth moved up by a moderate rise of 8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Curo Prime Pharmax?
In 2019, Curo Prime Pharmax had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Dec 2023 | ₹1.20 M | Open |
Hdfc Bank Limited Creation Date: 23 Jul 2021 | ₹0.70 M | Satisfied |
Others Creation Date: 30 Aug 2019 | ₹0.90 M | Satisfied |
How Many Employees Work at Curo Prime Pharmax?
Unlock and access historical data on people associated with Curo Prime Pharmax, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Curo Prime Pharmax, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Curo Prime Pharmax's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
